vs
IOVANCE BIOTHERAPEUTICS, INC.（IOVA）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
IOVANCE BIOTHERAPEUTICS, INC.的季度营收约是RE/MAX Holdings, Inc.的1.2倍（$86.8M vs $71.1M），IOVANCE BIOTHERAPEUTICS, INC.同比增速更快（17.7% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $-61.9M），过去两年IOVANCE BIOTHERAPEUTICS, INC.的营收复合增速更高（1001.6% vs -4.7%）
艾欧万斯生物治疗公司是一家总部位于加利福尼亚州圣卡洛斯的生物制药初创企业，专注于开发针对癌症的肿瘤浸润淋巴细胞（TIL）疗法，致力于为癌症患者提供创新型的免疫治疗方案。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
IOVA vs RMAX — 直观对比
营收规模更大
IOVA
是对方的1.2倍
$71.1M
营收增速更快
IOVA
高出19.6%
-1.8%
自由现金流更多
RMAX
多$95.4M
$-61.9M
两年增速更快
IOVA
近两年复合增速
-4.7%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $86.8M | $71.1M |
| 净利润 | — | $1.4M |
| 毛利率 | 67.4% | — |
| 营业利润率 | -84.7% | 13.1% |
| 净利率 | — | 2.0% |
| 营收同比 | 17.7% | -1.8% |
| 净利润同比 | — | -75.2% |
| 每股收益（稀释后） | — | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收IOVARMAX
| Q4 25 | $86.8M | $71.1M | ||
| Q3 25 | $67.5M | $73.2M | ||
| Q2 25 | $60.0M | $72.8M | ||
| Q1 25 | $49.3M | $74.5M | ||
| Q4 24 | $73.7M | $72.5M | ||
| Q3 24 | $58.6M | $78.5M | ||
| Q2 24 | $31.1M | $78.5M | ||
| Q1 24 | $715.0K | $78.3M |
净利润IOVARMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-91.3M | $4.0M | ||
| Q2 25 | $-111.7M | $4.7M | ||
| Q1 25 | $-116.2M | $-2.0M | ||
| Q4 24 | — | $5.8M | ||
| Q3 24 | $-83.5M | $966.0K | ||
| Q2 24 | $-97.1M | $3.7M | ||
| Q1 24 | $-113.0M | $-3.4M |
毛利率IOVARMAX
| Q4 25 | 67.4% | — | ||
| Q3 25 | 43.0% | — | ||
| Q2 25 | 5.5% | — | ||
| Q1 25 | -0.8% | — | ||
| Q4 24 | 68.7% | — | ||
| Q3 24 | 46.2% | — | ||
| Q2 24 | -0.8% | — | ||
| Q1 24 | — | — |
营业利润率IOVARMAX
| Q4 25 | -84.7% | 13.1% | ||
| Q3 25 | -140.7% | 25.0% | ||
| Q2 25 | -189.8% | 19.3% | ||
| Q1 25 | -245.8% | 7.2% | ||
| Q4 24 | -117.5% | 5.9% | ||
| Q3 24 | -152.1% | 19.4% | ||
| Q2 24 | -327.6% | 20.6% | ||
| Q1 24 | -16464.6% | 5.8% |
净利率IOVARMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | -135.3% | 5.4% | ||
| Q2 25 | -186.2% | 6.4% | ||
| Q1 25 | -235.5% | -2.6% | ||
| Q4 24 | — | 8.0% | ||
| Q3 24 | -142.7% | 1.2% | ||
| Q2 24 | -312.2% | 4.7% | ||
| Q1 24 | -15800.8% | -4.3% |
每股收益（稀释后）IOVARMAX
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | $-0.33 | — | ||
| Q1 25 | $-0.36 | — | ||
| Q4 24 | $-0.24 | — | ||
| Q3 24 | $-0.28 | — | ||
| Q2 24 | $-0.34 | — | ||
| Q1 24 | $-0.42 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $297.0M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $698.6M | $452.4M |
| 总资产 | $913.2M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资IOVARMAX
| Q4 25 | $297.0M | $118.7M | ||
| Q3 25 | $300.8M | $107.5M | ||
| Q2 25 | $301.2M | $94.3M | ||
| Q1 25 | $359.7M | $89.1M | ||
| Q4 24 | $323.8M | $96.6M | ||
| Q3 24 | $397.5M | $83.8M | ||
| Q2 24 | $412.5M | $66.1M | ||
| Q1 24 | $356.2M | $82.1M |
总债务IOVARMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益IOVARMAX
| Q4 25 | $698.6M | $452.4M | ||
| Q3 25 | $702.3M | $448.1M | ||
| Q2 25 | $698.5M | $442.4M | ||
| Q1 25 | $767.9M | $433.5M | ||
| Q4 24 | $710.4M | $429.5M | ||
| Q3 24 | $773.5M | $423.1M | ||
| Q2 24 | $768.5M | $418.4M | ||
| Q1 24 | $680.0M | $412.0M |
总资产IOVARMAX
| Q4 25 | $913.2M | $582.5M | ||
| Q3 25 | $904.9M | $582.2M | ||
| Q2 25 | $907.4M | $574.8M | ||
| Q1 25 | $966.7M | $571.4M | ||
| Q4 24 | $910.4M | $581.6M | ||
| Q3 24 | $991.1M | $578.6M | ||
| Q2 24 | $964.3M | $571.4M | ||
| Q1 24 | $869.8M | $566.7M |
负债/权益比IOVARMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-52.6M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $-61.9M | $33.5M |
| 自由现金流率自由现金流/营收 | -71.3% | 47.1% |
| 资本支出强度资本支出/营收 | 10.7% | 10.4% |
| 现金转化率经营现金流/净利润 | — | 28.39× |
| 过去12个月自由现金流最近4个季度 | $-336.2M | $56.8M |
8季度趋势，按日历期对齐
经营现金流IOVARMAX
| Q4 25 | $-52.6M | $40.9M | ||
| Q3 25 | $-78.7M | $17.7M | ||
| Q2 25 | $-67.4M | $4.6M | ||
| Q1 25 | $-103.7M | $5.7M | ||
| Q4 24 | $-73.3M | $59.7M | ||
| Q3 24 | $-59.0M | $17.6M | ||
| Q2 24 | $-98.4M | $15.9M | ||
| Q1 24 | $-122.3M | $9.4M |
自由现金流IOVARMAX
| Q4 25 | $-61.9M | $33.5M | ||
| Q3 25 | $-89.5M | $16.4M | ||
| Q2 25 | $-74.9M | $2.9M | ||
| Q1 25 | $-109.9M | $4.0M | ||
| Q4 24 | $-77.5M | $53.0M | ||
| Q3 24 | $-61.3M | $16.3M | ||
| Q2 24 | $-98.9M | $14.0M | ||
| Q1 24 | $-126.5M | $6.8M |
自由现金流率IOVARMAX
| Q4 25 | -71.3% | 47.1% | ||
| Q3 25 | -132.7% | 22.4% | ||
| Q2 25 | -124.9% | 4.0% | ||
| Q1 25 | -222.8% | 5.3% | ||
| Q4 24 | -105.1% | 73.2% | ||
| Q3 24 | -104.6% | 20.8% | ||
| Q2 24 | -317.9% | 17.8% | ||
| Q1 24 | -17685.3% | 8.6% |
资本支出强度IOVARMAX
| Q4 25 | 10.7% | 10.4% | ||
| Q3 25 | 16.1% | 1.8% | ||
| Q2 25 | 12.4% | 2.2% | ||
| Q1 25 | 12.6% | 2.3% | ||
| Q4 24 | 5.7% | 9.1% | ||
| Q3 24 | 3.9% | 1.7% | ||
| Q2 24 | 1.4% | 2.4% | ||
| Q1 24 | 583.4% | 3.3% |
现金转化率IOVARMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | — | 4.45× | ||
| Q2 25 | — | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 10.28× | ||
| Q3 24 | — | 18.22× | ||
| Q2 24 | — | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IOVA
| Amtagvi | $64.9M | 75% |
| Proleukin | $21.9M | 25% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
